PLPL (PLPL) Stock Price & Analysis
PLPL (PLPL) rose 900.00% to USD 0 as of June 10, 2026 at 02:19 UTC, according to Nexqual real-time market data.
PLPL last closed at USD 0; the session ranged USD 0–0 on volume of 773,640 shares. Market capitalization is $4.49M, with a 52-week range of USD 0–0 (OID). Source: Nexqual, June 10, 2026 at 02:19 UTC.
Key Statistics (as of June 10, 2026 at 02:19 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 900.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 773,640 shares |
| Market Cap | $4.49M |
| Exchange | OID |
Technical Analysis (PLPL)
Nexqual's technical model rates PLPL "BUY" based on 1 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:19 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Above (USD 0) |
Analyst Ratings (PLPL)
Wall Street analysts rate PLPL "None", per Nexqual as of June 10, 2026 at 02:19 UTC.
| Consensus Rating | None |
|---|
Earnings (PLPL)
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Financials & Fundamentals (PLPL)
| Total Revenue | $338,483 |
|---|---|
| Revenue Growth (YoY) | +97.90% |
| Gross Margin | -168.10% |
| Operating Margin | -889.87% |
| Profit Margin | +0.00% |
| Current Ratio | 0.01 |
| Total Cash | $22,091 |
| Total Debt | $16.83M |
| Free Cash Flow | $-330,704 |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Financial Health Score (PLPL)
Nexqual rates PLPL's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:19 UTC.
| Growth | Strong — Revenue +98% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $22K cash vs $17M debt |
| Cash Flow | Weak — FCF negative: -$331K, burning cash |
| Efficiency | Mixed — No data |
Ownership (PLPL)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 44.89B |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Leadership (PLPL)
PLPL is led by Roger Baylis-Duffield (age 82), Co-Founder, Chairman and Chief Executive Officer, per Nexqual as of June 10, 2026 at 02:19 UTC.
| Co-Founder, Chairman and Chief Executive Officer | Roger Baylis-Duffield (age 82) |
|---|---|
| President, Chief Operating Officer and Director | Callum Baylis-Duffield (age 40) |
| Vice President of Sales and Marketing | Ezra Jones |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NTRR | Neutra Corp. | USD 0 | ▲ 0% |
| EDXC | ENDEXX Corp. | USD 0 | ▲ 0% |
| FSPM | FUSION PHARM INC | USD 0 | ▲ 0% |
| FITX | CREATIVE EDGE NUTRITION INC | USD 0 | ▲ 0% |
| EAPH | EASTON PHARMACEUTICALS INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:19 UTC. This page is informational and not investment advice.